On July 6, Hengrui Pharma rose 4.01% in regular trading, reaching HKD 62.45 per share, with turnover of approximately HKD 125 million. The pharmaceutical sector rallied broadly, with Haixi Pharma up 9.23%, CSPC Pharma up 8.65%, and CSPC Holdings up 4.5%.

The stock was driven by a cluster of recent regulatory milestones. The company's subsidiary received acceptance and priority review designation for the marketing application of recombinant trastuzumab injection. Additionally, the NMPA approved a Phase III clinical trial for SHR-8068 injection combined with adebrelimab and bevacizumab plus TACE for unresectable hepatocellular carcinoma. Furthermore, the company's self-developed PD-L1 inhibitor adebrelimab received approval for a new perioperative indication in non-small cell lung cancer, becoming the first domestically developed PD-L1 inhibitor approved for this indication in China. The company also recently had its revulutamide tablets marketing application accepted by the European Medicines Agency, marking its first self-developed innovative drug submission to the EU.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)